SIMRIS GROUP APPOINTS BIOTECHNOLOGY EXPERT DR. TIFFANY J. VORA AS STRATEGIC ADVISOR
Simris Group AB today announced the appointment of Dr. Tiffany J. Vora as a Strategic Advisor.
Dr. Vora is a biotechnology scientist, entrepreneur, educator, and advisor with experience across molecular biology, genomics, biotechnology innovation, and drug discovery. Through her work with technology companies, startups, scientific organizations, and the broader innovation ecosystem, she has developed an extensive network across the U.S. biotechnology sector, particularly in Silicon Valley and the San Francisco Bay Area.
The appointment of Dr. Vora follows the recent appointment of Professor Andreas Pahl as Chief Executive Officer of Simris Biologics, a subsidiary focused on unlocking the next generation of effective, naturally derived, novel payloads for antibody-drug conjugates (ADCs). In her role as Strategic Advisor to the Group, Dr. Vora will support engagement with the broader U.S. biotechnology, financing and innovation ecosystem, while providing advice and support to Professor Pahl and the Simris Biologics team as they advance the Company’s ADC platform.
Daniel Kubitza, interim Chief Executive Officer of Simris Group, said: “We are delighted to welcome Tiffany as Strategic Advisor to Simris Group. Dr. Vora brings deep scientific expertise and an extensive network across the U.S. biotechnology ecosystem. Her insights will be invaluable as Simris Group strengthens its industry and investor engagement, while supporting the continued advancement of Simris Biologics' innovative ADC platform.”
Dr. Tiffany J. Vora, Strategic Advisor to Simris Group, added: “Simris Group has built a strong scientific foundation and a differentiated approach to ADC payload discovery based on nature-derived technologies. I look forward to working with Andreas and the team to advance its innovative ADC platform, helping create value for both patients and shareholders.”
Dr. Vora is currently a Singularity Fellow in Biotechnology and a contributor to EY Executive Learning programs. She also serves as a Non-resident Senior Fellow at the Atlantic Council's GeoTech Center and holds leadership and advisory roles with organizations including Humanity in Deep Space and Explore Mars. Earlier in her career, she worked in drug target validation at Bristol-Myers Squibb before founding and advising several science and innovation-focused ventures. Dr. Vora holds a PhD in Molecular Biology from Princeton University and undergraduate degrees in Biology and Chemistry from New York University.
For more information, please contact:
Daniel Kubitza
Interim CEO of Simris Group AB
Tel: +33 6 71 04 21 52
Email: daniel.kubitza@simris.com
Optimum Strategic Communications
Zoe Bolt, Katie Flint, Ben Cowe
Tel: +44 (2) 03 922 1906
Email:simris@optimumcomms.com
About Simris Group AB (PUBL):
Simris Group is a biologics company identifying and commercializing high-value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals.
Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.
Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.